Biologic Therapy for Osteoarthritis in Baltimore, MD

The numbers that actually change how you stock in Baltimore

If a sales sheet cannot tell you that Baltimore is JL (Novitas Solutions) and that adult diabetes here is 14.4% (PLACES 2023), it is selling units, not a program. That is the osteoarthritis biologic therapy conversation we actually have.

The chart problems we still see in MD

• Adult arthritis here is 25% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 10.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Maryland.
• JL (Novitas Solutions) is the contractor that will review CTP units, application frequency, and wound measurements for Maryland Part B claims. Practices that skip MAC education typically see denials before they see outcomes.
• Maryland Department of Health publishes state chronic-disease context that clinics can cite in patient education. Pair that with FDA 361 labeling — homologous use, minimal manipulation — so marketing does not outrun the product's actual regulatory lane.

City rate, state belt, federal LCD — keep the grains

Three grains, kept separate on purpose. City: Census 585,708 and CDC PLACES crude rates. State: Maryland Department of Health, Diabetes Belt not in the core list. Federal: 21 CFR 1271 and Novitas Solutions LCDs. CDC PLACES (2023, crude) estimates 14.4% of adults in Baltimore have diagnosed diabetes — 2.4 points above the U.S. 12% figure.

A practical checklist for Baltimore